Two faces for Janus: Recombinant human erythropoiesis-stimulating agents and cancer mortality

Expert Review of Hematology

Volumn 2, Issue 5, 2009, Pages 513-515

  Addeo, Raffaele ^a   Caraglia, Michele ^b   Frega, Nicola ^c   Del Prete, Salvatore ^a  

^a SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c Mauro Scarlato Hospital   (Italy)

Author keywords

Anemia; Blood transfusions; Erythropoiesis stimulating agents; Meta analysis; Venous thromboembolic events

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT HUMAN ERYTHROPOIESIS STIMULATING AGENT; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TRANSFUSION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; FOLLOW UP; HUMAN; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SOLID TUMOR;

EID: 77953383958     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.41     Document Type: Note

References (13)

1. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human ESAs and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373(9674), 1532-1542 (2009).
2. Addeo R, Caraglia M, Del Prete S. Highlights of the Pananemia National meeting of the Italian Southern Oncological Group (GOIM): pharmacological and molecular treatment of cancer-induced anemia. Sorrento, Italy, 19-20 December 2008. Expert Opin. Pharmacother. 10(6), 1089-1093 (2009).
3. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362, 1255-1260 (2003).
4. Leyland-Jones B; BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 4, 459-460 (2003). (Pubitemid 37009952)
5. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin b on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxanebased chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J. Clin. Oncol. 26(4), 592-598 (2006).
6. Wright JR, Ung YC, Julian JA et al. Randomized, double blind, placebo controlled trial of erythropoietin in non-small-cell lung cancer with diseaserelated anemia. J. Clin. Oncol. 25, 1027-1032 (2007).
7. Smith RE Jr, Aapro MS, Ludwig H et al. Darbepoetin a for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a Phase III, multicenter, randomized, doubleblind, placebo-controlled study. J. Clin. Oncol. 26, 1040-1050 (2008).
8. Rizzo JD, Somerfield MR, Hagerty KL et al; for American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J. Clin. Oncol. 26(1), 132-149 (2008)
9. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J. Clin. Oncol. 27(17), 2838-2847 (2009).
10. Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-b on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br. J. Cancer 99, 14-22 (2008)
11. Seidenfeld J, Piper M, Flamm C, et al: Epoetin treatment of anemia associated with cancer therapy: a systematic review and metaanalysis of controlled clinical trials. J. Natl Cancer Inst. 93, 1204-1214 (2001)
12. Gabrilove JL, Cleeland CS, Livingston RB et al. Clinical evaluation of once-weekly dosing of epoetin a in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-timesweekly dosing. J. Clin. Oncol. 19, 2875-2882 (2001).
13. Aapro MS, Link H. September 2007 Update on EORTC guidelines and anemia management with erythropoiesisstimulating agents. The Oncologist 13(Suppl. 3), 33-36 (2008).